Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study*
Liu S, Kelly-Hedrick M, Temkin N, Barber J, Komisarow J, Hatfield J, Ohnuma T, Manley G, Treggiari M, Colton K, Vavilala M, Grandhi R, Laskowitz D, Mathew J, Hernandez A, James M, Raghunathan K, Goldstein B, Markowitz A, Krishnamoorthy V, Investigators T. Association of Early Dexmedetomidine Utilization With Clinical and Functional Outcomes Following Moderate-Severe Traumatic Brain Injury: A Transforming Clinical Research and Knowledge in Traumatic Brain Injury Study*. Critical Care Medicine 2023, 52: 607-617. PMID: 37966330, PMCID: PMC10939970, DOI: 10.1097/ccm.0000000000006106.Peer-Reviewed Original ResearchModerate-severe traumatic brain injuryDisability Rating ScaleDexmedetomidine exposureHours of admissionTraumatic brain injuryFunctional outcomeHospital stayMechanical ventilationBrain injuryICP monitoringGlasgow Outcome Scale-ExtendedLevel 1 trauma centerClinical researchSevere traumatic brain injuryTraumatic Brain Injury (CENTER-TBI) studyFollowing secondary outcomesRetrospective cohort studySecond-line agentsPropensity-weighted modelsBrain Injury StudyLower DRS scoresEarly dexmedetomidineHospital mortalitySedation choiceUnexposed patients